Pegasys market share
Executive Summary
Roche Pegasys share of new prescriptions is 26% in the U.S. for the first quarter, up from 23% at the end of 2002, company tells analyst call April 10. The hepatitis C therapy may get a boost from the 15,000 patients who received peginterferon alfa-2a for three months free of charge ahead of the Copegus combination approval (1"The Pink Sheet" Oct. 21, 2002, p. 10)...
You may also be interested in...
Roche Pegasys Has $291 WAC; Launch Includes 12 Weeks Of Free Samples
Roche's Pegasys has a wholesale acquisition cost of $291 for one week of the hepatitis C therapy
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.